Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its stake in Twist Bioscience Co. (NASDAQ:TWST) by 5.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 370,849 shares of the company’s stock after purchasing an additional 17,715 shares during the period. New York State Common Retirement Fund’s holdings in Twist Bioscience were worth $13,669,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TWST. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Twist Bioscience by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock worth $30,000 after purchasing an additional 721 shares during the period. Teacher Retirement System of Texas raised its position in Twist Bioscience by 5.1% during the 3rd quarter. Teacher Retirement System of Texas now owns 16,206 shares of the company’s stock worth $328,000 after buying an additional 790 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of Twist Bioscience by 4.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 25,897 shares of the company’s stock worth $525,000 after acquiring an additional 1,062 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Twist Bioscience by 51.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after acquiring an additional 1,179 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of Twist Bioscience during the third quarter worth about $29,000.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of recent analyst reports. Scotiabank raised their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research report on Monday, February 5th. Barclays reduced their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. Finally, The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th.

Twist Bioscience Trading Up 1.6 %

TWST stock opened at $32.03 on Tuesday. The firm has a 50 day moving average of $34.57 and a 200-day moving average of $30.57. Twist Bioscience Co. has a 12-month low of $11.46 and a 12-month high of $43.21.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. The firm had revenue of $71.50 million during the quarter, compared to analysts’ expectations of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. Twist Bioscience’s revenue was up 31.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.74) earnings per share. Sell-side analysts forecast that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the transaction, the director now directly owns 64,169 shares in the company, valued at approximately $2,244,631.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now owns 64,169 shares in the company, valued at approximately $2,244,631.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Emily M. Leproust sold 1,487 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the transaction, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. Insiders have sold 13,211 shares of company stock worth $449,573 in the last three months. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.